Sapanisertib is an Orally Active and ATP-Dependent mTOR Inhibitor
Acute myelogenous leukemia (AML) is a heterogeneous disease. It often relapses after standard chemotherapy or proves refractory to available treatments. Therefore, It needs novel therapies for AML. In AML, many…